Logo image of CYAD

Celyad Oncology SA (CYAD) Stock Fundamental Analysis

USA - NASDAQ:CYAD - US1512052002 - ADR

0.47 USD
-0.06 (-11.1%)
Last: 5/18/2023, 8:00:00 PM
Fundamental Rating

1

Overall CYAD gets a fundamental rating of 1 out of 10. We evaluated CYAD against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of CYAD have multiple concerns. CYAD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYAD has reported negative net income.
CYAD had a negative operating cash flow in the past year.
In the past 5 years CYAD always reported negative net income.
CYAD had a negative operating cash flow in each of the past 5 years.
CYAD Yearly Net Income VS EBIT VS OCF VS FCFCYAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

The profitability ratios for CYAD are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYAD Yearly ROA, ROE, ROICCYAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800

1.3 Margins

CYAD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYAD Yearly Profit, Operating, Gross MarginsCYAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200K -400K -600K -800K

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, CYAD has about the same amount of shares outstanding.
Compared to 1 year ago, CYAD has an improved debt to assets ratio.
CYAD Yearly Shares OutstandingCYAD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
CYAD Yearly Total Debt VS Total AssetsCYAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

CYAD has an Altman-Z score of -8.51. This is a bad value and indicates that CYAD is not financially healthy and even has some risk of bankruptcy.
CYAD has a Altman-Z score of -8.51. This is in the lower half of the industry: CYAD underperforms 74.29% of its industry peers.
CYAD has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.03, CYAD perfoms like the industry average, outperforming 41.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -8.51
ROIC/WACCN/A
WACCN/A
CYAD Yearly LT Debt VS Equity VS FCFCYAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M 100M

2.3 Liquidity

CYAD has a Current Ratio of 1.42. This is a normal value and indicates that CYAD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.42, CYAD is doing worse than 83.02% of the companies in the same industry.
A Quick Ratio of 1.42 indicates that CYAD should not have too much problems paying its short term obligations.
CYAD's Quick ratio of 1.42 is on the low side compared to the rest of the industry. CYAD is outperformed by 82.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.42
CYAD Yearly Current Assets VS Current LiabilitesCYAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CYAD have decreased by -5.35% in the last year.
EPS 1Y (TTM)-5.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-69.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYAD Yearly Revenue VS EstimatesCYAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2M 4M 6M 8M
CYAD Yearly EPS VS EstimatesCYAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYAD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYAD Price Earnings VS Forward Price EarningsCYAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYAD Per share dataCYAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYAD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Celyad Oncology SA

NASDAQ:CYAD (5/18/2023, 8:00:00 PM)

0.47

-0.06 (-11.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)08-03 2023-08-03/amc
Inst Owners0.04%
Inst Owner Change-67.01%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.62M
Revenue(TTM)N/A
Net Income(TTM)-40.94M
Analysts40
Price Target0.48 (2.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.18%
PT rev (3m)-12.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.29
P/tB 2.86
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0
BVpS0.21
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.42
Altman-Z -8.51
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)17.27%
Cap/Depr(5y)49.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-69.6%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y78.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.13%
OCF growth 3YN/A
OCF growth 5YN/A

Celyad Oncology SA / CYAD FAQ

What is the ChartMill fundamental rating of Celyad Oncology SA (CYAD) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CYAD.


What is the valuation status of Celyad Oncology SA (CYAD) stock?

ChartMill assigns a valuation rating of 1 / 10 to Celyad Oncology SA (CYAD). This can be considered as Overvalued.


What is the profitability of CYAD stock?

Celyad Oncology SA (CYAD) has a profitability rating of 1 / 10.


Can you provide the financial health for CYAD stock?

The financial health rating of Celyad Oncology SA (CYAD) is 2 / 10.